Eton Pharmaceuticals, Inc. (ETON) financials: revenue, earnings and cash flow
Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$5M, a net margin of -5.8%; the best year in this period was 2023 with -$936000.
Over the twelve months to September 30, 2026, revenue was $141M and net income $50M.
Free cash flow was $10M in fiscal 2025 and positive in 4 of the 8 years shown.
The diluted share count rose 319% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $141M | $80M | $39M | $32M | $21M | $22M | $39000 | $959000 | — |
| Gross profit | $98M | $43M | $23M | $21M | $14M | $19M | -$397000 | $506000 | — |
| Operating income | $41M | -$844000 | -$3M | -$1M | -$8M | -$1M | -$27M | -$19M | -$10M |
| Net income | $50M | -$5M | -$4M | -$936000 | -$9M | -$2M | -$28M | -$18M | -$13M |
| EPS (diluted) | $1.50 | $-0.17 | $-0.15 | $-0.04 | $-0.36 | $-0.08 | $-1.33 | $-1.03 | $-5.80 |
| R&D | $10M | $8M | $3M | $3M | $4M | $6M | $14M | $12M | $6M |
| Revenue growth | — | +104.9% | +23.3% | +48.9% | −2.7% | +55879.5% | −95.9% | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $38M | $11M | $969000 | $7M | $5M | -$5M | -$22M | -$18M | -$8M |
| Capital spending | -$132000 | -$333000 | -$26000 | $0 | -$38000 | -$9000 | -$50000 | -$1M | -$236000 |
| Free cash flow | $38M | $10M | $943000 | $7M | $5M | -$5M | -$22M | -$19M | -$8M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $7M | $6M | $3M | $3M | $4M | $3M | $3M | $2M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $26M | $15M | $21M | $16M | $14M | $21M | $12M | $27M |
| Debt | — | $31M | $30M | $5M | $6M | $5M | $7M | $5M | — |
| Equity | — | $26M | $24M | $15M | $13M | $18M | $18M | $11M | $26M |
| Total assets | — | $92M | $76M | $32M | $25M | $27M | $26M | $17M | $28M |
| Shares (diluted) | 33M | 27M | 26M | 26M | 25M | 25M | 21M | 18M | 6M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 69.2% | 53.5% | 60.0% | 66.6% | 67.4% | 87.1% | -1018.0% | 52.8% | — |
| Operating margin | 28.8% | -1.1% | -6.7% | -3.8% | -38.9% | -6.9% | -69515.4% | -1939.6% | — |
| Net margin | 35.3% | -5.8% | -9.8% | -3.0% | -42.4% | -8.9% | -71717.9% | -1910.3% | — |
| FCF margin | 27.1% | 12.8% | 2.4% | 21.5% | 22.5% | -21.7% | -57425.6% | -1993.9% | — |
| ROIC | — | -1.2% | -3.8% | -4.5% | -44.3% | -6.5% | -88.3% | -97.3% | -31.0% |
| ROE | — | -17.6% | -15.7% | -6.0% | -69.0% | -11.1% | -158.7% | -173.7% | -48.4% |
Frequently asked questions
What is Eton Pharmaceuticals’s annual revenue?
$80M in fiscal 2025 and $141M over the twelve months to September 30, 2026.
How much profit does Eton Pharmaceuticals make?
Net income was -$5M in fiscal 2025 (net margin -5.8%).
Is Eton Pharmaceuticals’s revenue growing?
Yes: revenue rose 104.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.